BidaskClub upgraded shares of Trupanion (NASDAQ:TRUP) from a hold rating to a buy rating in a report published on Monday, December 18th.
Other analysts also recently issued research reports about the stock. CL King assumed coverage on shares of Trupanion in a research report on Tuesday, November 21st. They set a neutral rating for the company. Zacks Investment Research upgraded shares of Trupanion from a hold rating to a buy rating and set a $37.00 price objective for the company in a research report on Wednesday, November 8th. Finally, Canaccord Genuity restated a buy rating and set a $35.00 price objective (up previously from $29.00) on shares of Trupanion in a research report on Tuesday, October 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. Trupanion has an average rating of Buy and an average price target of $28.83.
Trupanion (NASDAQ:TRUP) traded down $0.66 during midday trading on Monday, reaching $34.38. 294,233 shares of the company’s stock traded hands, compared to its average volume of 184,146. The company has a quick ratio of 1.87, a current ratio of 1.87 and a debt-to-equity ratio of 0.15. Trupanion has a 12 month low of $13.71 and a 12 month high of $35.07.
Trupanion (NASDAQ:TRUP) last issued its quarterly earnings data on Thursday, November 2nd. The financial services provider reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.04. The business had revenue of $63.12 million during the quarter, compared to the consensus estimate of $61.44 million. Trupanion had a negative net margin of 1.05% and a negative return on equity of 7.41%. The company’s revenue was up 30.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.06) EPS. research analysts expect that Trupanion will post -0.04 EPS for the current fiscal year.
In related news, insider Asher Bearman sold 4,039 shares of the company’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $28.40, for a total value of $114,707.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Tricia Plouf sold 1,000 shares of the company’s stock in a transaction on Tuesday, November 7th. The shares were sold at an average price of $32.11, for a total transaction of $32,110.00. Following the completion of the sale, the chief financial officer now owns 14,000 shares of the company’s stock, valued at approximately $449,540. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,039 shares of company stock valued at $661,393. 31.24% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in TRUP. JPMorgan Chase & Co. purchased a new stake in Trupanion in the 3rd quarter valued at $143,000. Bank of Montreal Can raised its position in Trupanion by 309.2% during the 2nd quarter. Bank of Montreal Can now owns 9,044 shares of the financial services provider’s stock worth $201,000 after buying an additional 6,834 shares during the last quarter. Voya Investment Management LLC purchased a new position in Trupanion during the 2nd quarter worth $215,000. Oppenheimer Asset Management Inc. purchased a new position in Trupanion during the 3rd quarter worth $221,000. Finally, Wells Fargo & Company MN raised its position in Trupanion by 13.5% during the 2nd quarter. Wells Fargo & Company MN now owns 11,261 shares of the financial services provider’s stock worth $252,000 after buying an additional 1,342 shares during the last quarter. Hedge funds and other institutional investors own 63.25% of the company’s stock.
Trupanion, Inc provides medical insurance plans for cats and dogs throughout the United States, Canada and Puerto Rico. The Company operates in two business segments: subscription business and other business. The subscription business segment includes monthly subscriptions for its medical plan, which are marketed to consumers.
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.